EUVIMEDEUVIMED entdecken
Crossref

Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis

Liz Morrell iD, William F Mawalla iD, Malale Tungu iD, Jingjing Jiang iD, Lulu Chirande iD, Anna Schuh iD, George M Ruhago iD, Sarah Wordsworth iD, AI-REAL Consortium

JCO Global Oncology · 2026

DOI: 10.1200/go-25-00752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Liz Morrell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Rituximab, Burkitt Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Burkitt lymphoma (BL) is a highly prevalent childhood cancer in sub-Saharan Africa. Outcomes are poor, with only 50% 2-year survival. Improving survival through intensifying chemotherapy treatment has proved challenging. Incorporating rituximab (a high-cost biological agent) into the current chemotherapy regimen is an alternative approach. A recent observational study in Tanzania and Uganda found improved 1-year survival, with no significant additional adverse events, when rituximab was added to chemotherapy. We present an economic evaluation of this regimen compared with current treatment. METHODS We conducted a cost-utility analysis from a Tanzanian health care perspective, over a patient lifetime, using a 4-state Markov model. Outcomes were measured in Disability-Adjusted Life Years (DALYs), and results were compared with three possible cost-effectiveness thresholds ($411 US dollars [USD], $1,211 USD and $3,633 USD). Survival, adverse events, and chemotherapy use came from the observational study (N = 72). Other resource used was derived from treatment protocols and clinical expertise, and unit costs (2023) were provided by Tanzanian hospitals. Survival was modeled parametrically over 2 years, after which survivors were assumed to be cured. We examined heterogeneity in cost-effectiveness by disease stage and performed sensitivity and scenario analyses. RESULTS Adding rituximab gave an incremental cost-effectiveness ratio (ICER) of $483 USD per DALY averted, slightly above the most stringent of the thresholds considered, and would be considered cost effective at any threshold above $501 USD. Rituximab was particularly cost effective in advanced-stage disease (ICER $395 USD). Results were sensitive to discount rate, drug costs particularly rituximab, and disease progression assumptions. Budget impact was estimated as Tanzanian Shillings 866 million ($333,800 USD) annually, from 5 years after implementation. CONCLUSION Adding rituximab to current chemotherapy is a plausibly cost-effective treatment that would save lives in childhood BL, particularly for advanced-stage patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabBurkitt LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansTanzaniaCost-Benefit AnalysisChildFemaleAdolescentYoung AdultCost-Effectiveness AnalysisMaleChild, PreschoolMarkov Chains

Substanzen

Rituximab

Autor:innen und Institutionen

  • Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
  • National Institute for Health and Care Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
  • Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Department of Developmental Studies, School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.
  • Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Department of Oncology, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Liz Morrell, William F Mawalla, Malale Tungu, Jingjing Jiang, Lulu Chirande, Anna Schuh, George M Ruhago, Sarah Wordsworth

Zitieren

APA

Morrell, L., Mawalla, W. F., Tungu, M., Jiang, J., Chirande, L., Schuh, A., Ruhago, G. M., Wordsworth, S., & AI-REAL Consortium (2026). Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis. JCO Global Oncology. https://doi.org/10.1200/go-25-00752

Vancouver

Morrell L, Mawalla WF, Tungu M, Jiang J, Chirande L, Schuh A, et al. Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis. JCO Global Oncology. 2026. doi:10.1200/go-25-00752

BibTeX
@article{Morrell2026,
  author = {Morrell, Liz and Mawalla, William F and Tungu, Malale and Jiang, Jingjing and Chirande, Lulu and Schuh, Anna and Ruhago, George M and Wordsworth, Sarah and AI-REAL Consortium, AI-REAL Consortium},
  title = {Addition of Rituximab to First-Line Treatment of Burkitt Lymphoma in Children and Young Adults in Tanzania: A Cost-Utility Analysis},
  journal = {JCO Global Oncology},
  year = {2026},
  doi = {10.1200/go-25-00752}
}
Kostenlos starten →